https://www.businesswire.com/news/home/20210728005557/en/ENYO-Pharma-Announces-Positive-Vonafexor-EYP001-Results-for-the-LIVIFY-Phase-2a-Study-in-F2-F3-NASH-Patients-over-12-weeks
ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3...
ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a in NASH patients